77 related articles for article (PubMed ID: 22928785)
1. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.
Meulenbeld HJ; Bleuse JP; Vinci EM; Raymond E; Vitali G; Santoro A; Dogliotti L; Berardi R; Cappuzzo F; Tagawa ST; Sternberg CN; Jannuzzo MG; Mariani M; Petroccione A; de Wit R
BJU Int; 2013 Jan; 111(1):44-52. PubMed ID: 22928785
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.
Chi KN; Beardsley E; Eigl BJ; Venner P; Hotte SJ; Winquist E; Ko YJ; Sridhar SS; Weber D; Saad F
Ann Oncol; 2012 Jan; 23(1):53-58. PubMed ID: 21765178
[TBL] [Abstract][Full Text] [Related]
3. Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.
Coombes RC; Badman PD; Lozano-Kuehne JP; Liu X; Macpherson IR; Zubairi I; Baird RD; Rosenfeld N; Garcia-Corbacho J; Cresti N; Plummer R; Armstrong A; Allerton R; Landers D; Nicholas H; McLellan L; Lim A; Mouliere F; Pardo OE; Ferguson V; Seckl MJ
Nat Commun; 2022 Jun; 13(1):3246. PubMed ID: 35688802
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
Dahut WL; Madan RA; Karakunnel JJ; Adelberg D; Gulley JL; Turkbey IB; Chau CH; Spencer SD; Mulquin M; Wright J; Parnes HL; Steinberg SM; Choyke PL; Figg WD
BJU Int; 2013 Jun; 111(8):1269-80. PubMed ID: 23419134
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
Beltran H; Oromendia C; Danila DC; Montgomery B; Hoimes C; Szmulewitz RZ; Vaishampayan U; Armstrong AJ; Stein M; Pinski J; Mosquera JM; Sailer V; Bareja R; Romanel A; Gumpeni N; Sboner A; Dardenne E; Puca L; Prandi D; Rubin MA; Scher HI; Rickman DS; Demichelis F; Nanus DM; Ballman KV; Tagawa ST
Clin Cancer Res; 2019 Jan; 25(1):43-51. PubMed ID: 30232224
[TBL] [Abstract][Full Text] [Related]
6. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
[TBL] [Abstract][Full Text] [Related]
7. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
[TBL] [Abstract][Full Text] [Related]
8. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
Owonikoko TK; Niu H; Nackaerts K; Csoszi T; Ostoros G; Mark Z; Baik C; Joy AA; Chouaid C; Jaime JC; Kolek V; Majem M; Roubec J; Santos ES; Chiang AC; Speranza G; Belani CP; Chiappori A; Patel MR; Czebe K; Byers L; Bahamon B; Li C; Sheldon-Waniga E; Kong EF; Williams M; Badola S; Shin H; Bedford L; Ecsedy JA; Bryant M; Jones S; Simmons J; Leonard EJ; Ullmann CD; Spigel DR;
J Thorac Oncol; 2020 Feb; 15(2):274-287. PubMed ID: 31655296
[TBL] [Abstract][Full Text] [Related]
9. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Loriot Y; Necchi A; Park SH; Garcia-Donas J; Huddart R; Burgess E; Fleming M; Rezazadeh A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Zhong B; Stuyckens K; Santiago-Walker A; De Porre P; O'Hagan A; Avadhani A; Siefker-Radtke AO;
N Engl J Med; 2019 Jul; 381(4):338-348. PubMed ID: 31340094
[TBL] [Abstract][Full Text] [Related]
10. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Heath E; Heilbrun L; Mannuel H; Liu G; Lara P; Monk JP; Flaig T; Zurita A; Mack P; Vaishampayan U; Stella P; Smith D; Bolton S; Hussain A; Al-Janadi A; Silbiger D; Usman M; Ivy SP
Oncologist; 2019 Sep; 24(9):1149-e807. PubMed ID: 31152080
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS).
Veitch Z; Zer A; Loong H; Salah S; Masood M; Gupta A; Bradbury PA; Hogg D; Wong A; Kandel R; Charames GS; Abdul Razak AR
Sci Rep; 2019 May; 9(1):7390. PubMed ID: 31089155
[TBL] [Abstract][Full Text] [Related]
12. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Falchook G; Coleman RL; Roszak A; Behbakht K; Matulonis U; Ray-Coquard I; Sawrycki P; Duska LR; Tew W; Ghamande S; Lesoin A; Schwartz PE; Buscema J; Fabbro M; Lortholary A; Goff B; Kurzrock R; Martin LP; Gray HJ; Fu S; Sheldon-Waniga E; Lin HM; Venkatakrishnan K; Zhou X; Leonard EJ; Schilder RJ
JAMA Oncol; 2019 Jan; 5(1):e183773. PubMed ID: 30347019
[TBL] [Abstract][Full Text] [Related]
13. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.
DuBois SG; Mosse YP; Fox E; Kudgus RA; Reid JM; McGovern R; Groshen S; Bagatell R; Maris JM; Twist CJ; Goldsmith K; Granger MM; Weiss B; Park JR; Macy ME; Cohn SL; Yanik G; Wagner LM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Boucher N; Czarnecki S; Luo C; Tsao-Wei D; Matthay KK; Marachelian A
Clin Cancer Res; 2018 Dec; 24(24):6142-6149. PubMed ID: 30093449
[TBL] [Abstract][Full Text] [Related]
14. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Monk P; Liu G; Stadler WM; Geyer S; Huang Y; Wright J; Villalona-Calero M; Wade J; Szmulewitz R; Gupta S; Mortazavi A; Dreicer R; Pili R; Dawson N; George S; Garcia JA
Invest New Drugs; 2018 Oct; 36(5):919-926. PubMed ID: 30083962
[TBL] [Abstract][Full Text] [Related]
15. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
Diamond JR; Eckhardt SG; Pitts TM; van Bokhoven A; Aisner D; Gustafson DL; Capasso A; Sams S; Kabos P; Zolman K; Colvin T; Elias AD; Storniolo AM; Schneider BP; Gao D; Tentler JJ; Borges VF; Miller KD
Breast Cancer Res; 2018 Aug; 20(1):82. PubMed ID: 30071865
[TBL] [Abstract][Full Text] [Related]
16. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
Hussain M; Daignault-Newton S; Twardowski PW; Albany C; Stein MN; Kunju LP; Siddiqui J; Wu YM; Robinson D; Lonigro RJ; Cao X; Tomlins SA; Mehra R; Cooney KA; Montgomery B; Antonarakis ES; Shevrin DH; Corn PG; Whang YE; Smith DC; Caram MV; Knudsen KE; Stadler WM; Feng FY; Chinnaiyan AM
J Clin Oncol; 2018 Apr; 36(10):991-999. PubMed ID: 29261439
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.
Borisa AC; Bhatt HG
Eur J Med Chem; 2017 Nov; 140():1-19. PubMed ID: 28918096
[TBL] [Abstract][Full Text] [Related]
18. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T;
Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371
[TBL] [Abstract][Full Text] [Related]
19. An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.
Necchi A; Lo Vullo S; Mariani L; Raggi D; Giannatempo P; Calareso G; Togliardi E; Crippa F; Di Genova N; Perrone F; Colecchia M; Paolini B; Pelosi G; Nicolai N; Procopio G; Salvioni R; De Braud FG
Invest New Drugs; 2016 Apr; 34(2):236-42. PubMed ID: 26873642
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.
Amin M; Minton SE; LoRusso PM; Krishnamurthi SS; Pickett CA; Lunceford J; Hille D; Mauro D; Stein MN; Wang-Gillam A; Trull L; Lockhart AC
Invest New Drugs; 2016 Feb; 34(1):84-95. PubMed ID: 26620496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
